NeuBase Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2025-01-07

Corporate Action: Liquidation

Type: New

Accession Number: 000110465925001664

Comments: On January 2, 2025, NeuBase Therapeutics, Inc. terminated its lease agreement for its headquarters and notified that the company would not maintain a headquarters. The company announced that it has adopted a Plan of Distribution in accordance with its ongoing liquidation and dissolution as outlined in its Plan of Dissolution. The Board approved the distribution of an initial aggregate of approximately $500,000 to stockholders of record as of June 26, 2024, with an initial distribution of $0.13 per share. Additionally, on the same day, Todd P. Branning resigned as interim Chief Executive Officer and Chief Financial Officer, effective January 3, 2025, but was appointed to the Board on January 4, 2025. Dov A. Goldstein, M.D. also resigned from the Board on that date, with both resignations not resulting from any disagreements with the company.

Document Link: View Document